Galectin-3 in prostate cancer and heart diseases: a biomarker for these two frightening pathologies?

Data de publicação: 01/01/2023 Data Ahead of Print: 30/12/2022

Autores da FMUP

Joaquim Adelino Correia Ferreira Leite Moreira

Autor

Participantes de fora da FMUP

Lima T.
Perpétuo L.
Henrique R.
Fardilha M.
Bastos J.
Vitorino R.

Unidades de investigação

Cirurgia e Fisiologia
Laboratório Associado RISE- Rede de Investigação em Saúde

Investigador

Fernando Carlos De Landér Schmitt
RISE-Health

Investigador

Fernando Carlos De Landér Schmitt

Abstract

Galectin-3 (Gal-3) belongs to galectin protein family, a type of ß-galactose-binding lectin having more than one evolutionarily conserved domain of carbohydrate recognition. Gal-3 is mainly located in the cytoplasm, but it also enters the nucleus and is secreted into the extracellular environment and biological fluids such as urine, saliva, and serum. It plays an important role in many biological functions, such as angiogenesis, apoptosis, cell differentiation, cell growth, fibrosis, inflammation, host defense, cellular modification, splicing of pre-mRNA, and transformation. Many previous studies have shown that Gal-3 can be used as a diagnostic or prognostic biomarker for heart ailments, kidney diseases, and other major illnesses including cancer. Moreover, it may also play a major role in risk stratification in different diseases, and in this review, we have summarized the potential roles and application of Gal-3 as diagnostic, prognostic, and risk stratifying biomarker from previously reported studies in heart diseases and cancer, with special emphasis on prostate cancer. © 2022, The Author(s).

Dados da publicação

ISSN/ISSNe:: 0301-4851, 1573-4978
Tipo:: Review
Páginas:: 2763-2778
DOI:: 10.1007/s11033-022-08207-1
Link para outro recurso:: www.scopus.com

Documentos

Não há documentos

Métricas

Filiações

Lima T.:: iBiMED, Department of Medical Sciences, University of Aveiro, Aveiro, Portugal

Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP) / RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto) / Porto Comprehensive Cancer Center (Porto.CCC), Rua Dr. António Bernardino de Almeida, Porto, 4200-072, Portugal
Perpétuo L.:: iBiMED, Department of Medical Sciences, University of Aveiro, Aveiro, Portugal

Departamento de Cirurgia e Fisiologia, Faculdade de Medicina da Universidade do Porto, UnIC, Porto, Portugal
Henrique R.:: Cancer Biology and Epigenetics Group, Research Center of IPO Porto (CI-IPOP) / RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto) / Porto Comprehensive Cancer Center (Porto.CCC), Rua Dr. António Bernardino de Almeida, Porto, 4200-072, Portugal

Department of Pathology, Portuguese Oncology Institute of Porto (IPO Porto), Rua Dr. António Bernardino de Almeida, Porto, 4200-072, Portugal

Department of Pathology and Molecular Immunology, School of Medicine and Biomedical Sciences, University of Porto (ICBAS-UP), Rua de Jorge Viterbo Ferreira, 228, Porto, 4050-313, Portugal
Fardilha M.:: iBiMED, Department of Medical Sciences, University of Aveiro, Aveiro, Portugal
Leite-Moreira A.:: Departamento de Cirurgia e Fisiologia, Faculdade de Medicina da Universidade do Porto, UnIC, Porto, Portugal
Bastos J.:: iBiMED, Department of Medical Sciences, University of Aveiro, Aveiro, Portugal
Vitorino R.:: iBiMED, Department of Medical Sciences, University of Aveiro, Aveiro, Portugal

Departamento de Cirurgia e Fisiologia, Faculdade de Medicina da Universidade do Porto, UnIC, Porto, Portugal

LAQV-REQUIMTE, Departamento de Química, Universidade de Aveiro, Aveiro, Portugal

Department of Chemistry, University of Aveiro, Aveiro, Portugal

Keywords

Biomarkers; Galectin 3; Galectins; Heart Diseases; Humans; Male; Prostatic Neoplasms; galectin 3; biological marker; galectin; galectin 3; angiogenesis; cell differentiation; cell growth; heart disease; host resistance; human; kidney disease; malignant neoplasm; prostate cancer; protein expression; Review; genetics; heart disease; male; metabolism; prostate tumor